Children's Oncology Group: What We Learned In The Merger Process

Gregory H. Reaman, MD Professor of Pediatrics The George Washington University School of Medicine and Health Sciences

Children's Oncology Group



- Children's Cancer Group
- Pediatric Oncology Group
- National Wilms' Tumor Study Group
- Intergroup
 Rhabdomyosarcoma
 Study Group

COG

- Why? Because we had to!
- No NCI mandate
- A result of the "Intergroup" process
- Scientific agenda required consolidation: study population considerations
- Recognized needless duplication
- Multi-discipline/ multi-disease

The National Childhood Cancer Mortality Rate and the Pediatric Cooperative Groups



Immediate Challenges / Considerations

- Timeline: Planning/ Transition/ Implementation
- Continue open studies/ plan new initiatives: Role of a "Transition Team"
- Membership: Individual/ Discipline/ Institutional
- Funding: Financial planning and funds distribution
- Administrative consolidation
- SDC consolidation

Organizational Challenges and Accomplishments

- Both administrative and scientific
- Adopt and ratify a new Constitution
- Redefine institutional and individual membership and complete certification (230 sites)
- Transfer responsibility of two U-01 and three U-10 awards and implement redistribution of funds
- Consolidate administrative and regulatory activities within a single group Operations Center
- Maintain legacy study conduct (80(III), 22(II), 7(I)) and initiate new group initiatives

Challenges and Accomplishments

- Consolidate data management operations and responsibilities in a single Research Data Center
- Develop a Distributed Statistics Department
- Develop and implement plans/ systems for transfer of data sets and management of legacy studies
- ♦ Expand web-based Remote Data Entry (RDE) to accommodate legacy and future study development – increased functionality: RDE1 → eRDEs
- Competitive U-10 applications 2002, 2007

Children's Oncology Group

- Largest childhood cancer research organization in the world
- Encompasses > 200 pediatric cancer programs in North America, Australia, New Zealand, Switzerland, and the Netherlands
- Multidisciplinary Research Enterprise
- Biopathology Center: National Resource for Pediatric Cancer Specimen Banking
- Centralized Reference and Resource Laboratories for Biology and Classification Studies
- Centralized Review Centers
- Established a national childhood cancer registry for its North American sites - CCRN

Accrual 2001-2007



Accomplishments

Organizational & Administrative

- PedCIRB needs survey implementation and affiliation
- EURAMOS study development of CTEP guidelines for International trials
- "NIH Roadmap" COG and PBMTC/ BMT-CTN
 Interoperable infrastructure
- Pilot and implementation of Childhood Cancer Research Network (CCRN)
- Clinical trials in RB and other rare tumors
- Sole source for Industry collaboration

Accomplishments

Clinical: Practice - Changing

- Clinical and biologic risk-based classification: ALL, AML, NBL
- Cytogenetic predictors of outcome: ALL, AML, NBL, Wilms'
- Prognostic significance of MRD: ALL, AML, NBL, NHL
- Refinements in risk-adjusted therapy approaches
- Long-term follow-up guidelines

Accomplishments

Translational Science

- Gene expression microarrays and cancer signaturesdiagnosis and prognosis
- Gene polymorphisms and association with outcome
- Proof of principle: functional imaging (PET) as biomarker in pediatrics
- Intra/ extramural NCI collaboration TCGA

 TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative
- CTD² (Cancer Target Discovery and Development Network)
 Children's Oncology Group